98 related articles for article (PubMed ID: 38664760)
1. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
[TBL] [Abstract][Full Text] [Related]
2. Sixth-Week Immune-Nutritional-Inflammatory Biomarkers: Can They Predict Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
Olgun P; Diker O
Curr Oncol; 2023 Dec; 30(12):10539-10549. PubMed ID: 38132403
[TBL] [Abstract][Full Text] [Related]
3. Effect of body mass index and cholesterol-rich apolipoprotein-B-containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors-based therapy: A retrospective analysis.
Hu Z; Zheng Y; Zheng J; Wang Y; Liao J; Liu Z; Li J; Cui H
Cancer Med; 2024 Jun; 13(11):e7241. PubMed ID: 38819098
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.
Cui R; Li Y; Yu X; Wei C; Jiang O
PLoS One; 2024; 19(6):e0304941. PubMed ID: 38865375
[TBL] [Abstract][Full Text] [Related]
5. Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Yang M; Cao H; Wang C; Yu C; Sun P
J Cancer Res Ther; 2024 Apr; 20(2):509-521. PubMed ID: 38687920
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors.
Shen J; Ye X; Hou H; Wang Y
Int Immunopharmacol; 2024 Jun; 134():112243. PubMed ID: 38735258
[TBL] [Abstract][Full Text] [Related]
7. [Advances in Pseudoprogression of Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Tong Y; Long Y; Zhang F; Li J
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):306-320. PubMed ID: 38769834
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of the Gustave Roussy Immune Score in Lung Cancer: A Meta-Analysis.
Ji Y; Wang W
Nutr Cancer; 2024 Jun; ():1-10. PubMed ID: 38841900
[TBL] [Abstract][Full Text] [Related]
9. Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Rebuzzi SE; Fornarini G; Banna GL; Rescigno P; Buti S
Eur J Cancer; 2024 Jul; 205():114097. PubMed ID: 38735162
[No Abstract] [Full Text] [Related]
10. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.
Takenaka Y; Oya R; Takemoto N; Inohara H
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1122-1135. PubMed ID: 34337889
[TBL] [Abstract][Full Text] [Related]
11. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
12. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
[TBL] [Abstract][Full Text] [Related]
13. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
[TBL] [Abstract][Full Text] [Related]
14. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]